Drug
Tiotropium (Spiriva®)
Tiotropium (Spiriva®) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_4
2
50%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Not yet recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (50.0%)
Phase 42 (50.0%)
Trials by Status
completed250%
not_yet_recruiting125%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_4
Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response
NCT06679465
completedphase_4
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
NCT00144196
terminatedphase_3
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00662740
completedphase_3
Spiriva® Assessment of FEV1 (SAFE)
NCT00277264
Clinical Trials (4)
Showing 4 of 4 trials
NCT06679465Phase 4
Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response
NCT00144196Phase 4
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
NCT00662740Phase 3
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00277264Phase 3
Spiriva® Assessment of FEV1 (SAFE)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4